Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
Authors
Keywords
Diffuse large B cell lymphoma, PKCβ inhibitor, BTK inhibitor, Targeted therapy, Drug combination
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-18
DOI
10.1186/s13046-019-1076-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
- (2018) Elena Battistello et al. BLOOD
- A multiprotein supercomplex controlling oncogenic signalling in lymphoma
- (2018) James D. Phelan et al. NATURE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Syk inhibitors in clinical development for hematological malignancies
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Targeting of B-cell receptor signalling in B-cell malignancies
- (2017) M. Jerkeman et al. JOURNAL OF INTERNAL MEDICINE
- Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
- (2017) K Karube et al. LEUKEMIA
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- (2016) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Notch signaling as a novel regulator of metabolism
- (2015) Pengpeng Bi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Protein kinase C in cellular transformation: a valid target for therapy?: Figure 1
- (2014) Anuradha Tarafdar et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines
- (2014) Maria Cosenza et al. HEMATOLOGICAL ONCOLOGY
- High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
- (2014) Lesley A. Mathews Griner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
- (2014) Chung-Shien Lee et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
- (2013) Girija Dasmahapatra et al. BRITISH JOURNAL OF HAEMATOLOGY
- New insights into Notch1 regulation of the PI3K–AKT–mTOR1 signaling axis: Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia
- (2013) Eric C. Hales et al. CELLULAR SIGNALLING
- Diffuse large B-cell lymphoma—treatment approaches in the molecular era
- (2013) Mark Roschewski et al. Nature Reviews Clinical Oncology
- Targeting pathological B cell receptor signalling in lymphoid malignancies
- (2013) Ryan M. Young et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
- (2012) Maria Cosenza et al. ANNALS OF HEMATOLOGY
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
- (2012) Monica Civallero et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells
- (2011) Juraj Bodo et al. APOPTOSIS
- Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines
- (2010) Monica Civallero et al. LEUKEMIA & LYMPHOMA
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started